| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Allylcarbamate does not have a specific biological target but functions as a chemical linker in bioconjugation. As a cleavable linker, it is used to connect a targeting moiety (e.g., an antibody) to a payload (e.g., a cytotoxic drug) in antibody-drug conjugates (ADCs). The allylcarbamate group can be cleaved under specific conditions, releasing the payload at the target site. This allows for targeted delivery of therapeutic agents, reducing off-target toxicity. Its utility as a cleavable linker makes it a valuable tool for ADC development and bioconjugation research.
|
|---|---|
| ln Vitro |
In vitro, allylcarbamate is used as a reagent in the synthesis of antibody-drug conjugates and other bioconjugates. The compound's allylcarbamate group allows for the attachment of payloads via various chemical reactions. Its cleavability enables controlled release of payloads under specific conditions. The compound is used in conjugation reactions with antibodies, peptides, and other targeting moieties. Its activity is related to its chemical reactivity rather than pharmacological activity. Detailed quantitative activity data are not applicable, as it is a chemical linker.
|
| ln Vivo |
In vivo, allylcarbamate is not used as a therapeutic agent itself but as a component of antibody-drug conjugates and other bioconjugates. When incorporated into an ADC, the allylcarbamate linker enables the targeted delivery of cytotoxic payloads to tumor cells. The linker is designed to be cleaved under specific conditions (e.g., in the tumor microenvironment), releasing the payload at the target site. Its in vivo behavior is determined by the properties of the conjugate rather than the linker itself. The compound is for research use only and is not approved for human therapeutic use.
|
| Enzyme Assay |
The in vitro conjugation assay for allylcarbamate typically involves the synthesis of antibody-drug conjugates. The compound is activated (if needed) and reacted with a targeting moiety (e.g., an antibody) and a payload (e.g., a cytotoxic drug) under appropriate conditions. The conjugation efficiency is assessed by HPLC, mass spectrometry, or SDS-PAGE. The stability of the linker is assessed under various conditions (e.g., pH, temperature, enzymatic cleavage). The release of the payload is measured by HPLC or LC-MS. Positive controls (e.g., known linkers) and negative controls (no linker) are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, antibody-drug conjugates containing allylcarbamate linkers are tested for their activity against target cells. Cells expressing the target antigen are treated with the ADC at varying concentrations, and cell viability is assessed using CellTiter-Glo or MTT assays. The specificity of the ADC is assessed using antigen-negative control cells. The release of the payload is confirmed by measuring intracellular payload concentrations. All experiments include appropriate controls (free payload, unconjugated antibody) and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, immunodeficient mice are subcutaneously inoculated with target antigen-positive tumor cells. When tumors are established, mice are treated with ADCs containing allylcarbamate linkers. Tumor volume is measured, and survival is assessed. Pharmacokinetic studies measure ADC and payload concentrations in plasma and tissues. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of allylcarbamate are not relevant, as it is a chemical linker rather than a therapeutic agent. The compound has a molecular weight of 144.17 and is a small, polar molecule. When incorporated into an ADC, the pharmacokinetics of the conjugate are determined by the properties of the antibody and the overall conjugate, rather than the linker alone. The compound should be stored in a cool, dry place protected from moisture and light. Detailed PK data are not available.
|
| Toxicity/Toxicokinetics |
The toxicology of allylcarbamate is primarily related to its use as a chemical reagent rather than a therapeutic agent. The compound should be handled with appropriate laboratory safety precautions, including the use of personal protective equipment. Inhalation, ingestion, or skin absorption may cause adverse effects. The compound is not genotoxic in standard in vitro assays. It is for research use only and is not approved for human therapeutic use.
|
| Additional Infomation |
Allylcarbamate is a cleavable linker used in the synthesis of antibody-drug conjugates and other bioconjugates. It has a molecular formula of C6H12N2O2 and a molecular weight of 144.17. The compound is not approved for human use and is intended for research purposes only. It is available as a high-purity research reagent for laboratory use. Its cleavable linker properties make it a valuable tool for ADC development and bioconjugation research.
|
| Molecular Formula |
C6H12N2O2
|
|---|---|
| Molecular Weight |
144.17168
|
| Exact Mass |
144.09
|
| CAS # |
223741-66-0
|
| Related CAS # |
Allyl (2-aminoethyl)carbamate hydrochloride;1049722-41-9
|
| PubChem CID |
16213720
|
| Appearance |
Colorless to light yellow liquid（Density：1.039 g/cm3）
|
| Density |
1.039g/cm3
|
| Boiling Point |
248.6ºC at 760 mmHg
|
| Flash Point |
104.1ºC
|
| Vapour Pressure |
0.0241mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
0.762
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
114
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCOC(NCCN)=O
|
| InChi Key |
ZEDOIHSWNTZHCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H12N2O2/c1-2-5-10-6(9)8-4-3-7/h2H,1,3-5,7H2,(H,8,9)
|
| Chemical Name |
prop-2-enyl N-(2-aminoethyl)carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.9363 mL | 34.6813 mL | 69.3626 mL | |
| 5 mM | 1.3873 mL | 6.9363 mL | 13.8725 mL | |
| 10 mM | 0.6936 mL | 3.4681 mL | 6.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
